February 7, 2024 8:02am

Have we pumped the pot for the upside or the end of share pricing growth

Pre-open indications: 2 Sell into Strength, 1 Positive and 3 Negative Indications

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  RMi provides a trusted source of share pricing intelligence. Join me … in the NO spin zone!

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

There is no breadline for share pricing and fact-based intelligence!

I also follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 

Tuesday: The pre-open Dow futures are DOWN -0.03% or (-13 points), the S&P futures are UP +0.13% or (+6 points) as the Nasdaq futures are UP +0.25% or (+45 points)

Stock futures were mixed slightly charged on Wednesday

European markets turned lower,

Asia-Pacific stocks were mostly higher while Japan fell.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Last night, indexes rose on Tuesday as the Dow closed UP +141.24 points or +0.37%, the S&P closed UP +11.42 points +0.23% while the Nasdaq closed DOWN +11.32 points or +0.07%

Economic Data Docket: MBA Mortgage Applications, Feb. 2 (-7.2% prior), consumer credit, December ($16.5 billion expected, $23.75 billion prior)

 

Tuesday’s night RegMed Investors (RMi) Closing Bell: “electronic trader were not conflicted, saw the decline, popped the cork to carbonate some fizz in the sector. With Monday’s advance/Decline (A/D) line was 11/23 and todays was 31/4” … https://www.regmedinvestors.com/articles/13317

 

Q1/24: February – 2 positive and 2 negative closes

  • January: 2 holidays, 11 negative and 8 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Sell into Strength:

Tuesday, Monday, Friday, Thursday’s and last Wednesday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Ultragenyx Pharmaceuticals (RARE) closed up +$1.13 after Monday’s +$1.74, Friday’s -$1.08, Thursday’s -$0.01, and last Wednesday’s -$0.77 with a positive +$0.10 or +0.22% pre-open indication

Vericel (VCEL) closed up +$0.94 after Monday’s +$0.33, Friday’s -$0.76, Thursday’s +$0.67 and Wednesday’s -$1.28 with neutral pre-open indication.

 

Negative Indications:

Tuesday, Monday, Friday, Thursday’s and last Wednesday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Beam Therapeutics (BEAM) closed up +$1.95 after Monday’s +$0.01, Friday’s -$0.51, Thursday’s +$2.03 and last Wednesday’s -$1.44, with a negative -$0.87 or -3.12%

Blueprint Medicine (BPMC) closed up +$0.51 after Monday’s -$2.92 and Friday’s -$0.30 with a negative -$1.16 or -1.50% pre-open indication.

Fate Therapeutics (FATE) closed down -$0.62 after Monday’s -$0.16, Friday’s -$0.24, Thursday’s +$0.60 and Wednesday’s +$0.58 with a neutral pre-open indication.

 

Positive Indication:

Monday, Friday, Thursday, Wednesday and last Tuesday’s closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Regenxbio (RGNX0 closed up +$0.73 after Monday’s +$0.08 and Friday’s -$0.44 with a positive +$1.94 or +14.87% pre-open indication.

 

The BOTTOM LINE: Deal the cards … you’ve been dealt!

The phrase is used when a person tries to show others that one hasn’t “shut the back door” and if you try to act too smart, you'll get hurt.

  • In other words, do your best with what you got.

The remainder of the month’s trading sessions will be critical as the RegMed sector will begin earnings’ LPS (loss-per-share) season, estimates and consensus which set market reaction. 

  • Coming attractions …Q4 and FY23 reporting season will ALSO report “runways” and those whose cash positions render their future questionable.

That is WHY I focus on INDICATIONS … Skim if you can trim, buy if it will fly and sell if compelled!

  • As I wrote on last week “When it comes to short-term investing or trading; the trend is NOT your friend.”  Just wait a session and the direction will change from tailwinds to headwinds … or NOT!

US stocks ended Tuesday's session in the green; even, the cell and gene therapy sector.

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.